blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2999967

EP2999967 - USE OF TENASCIN-C AS AN EXTRACELLULAR MARKER OF TUMOR-DERIVED MICROPARTICLES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  26.03.2021
Database last updated on 26.03.2026
FormerThe patent has been granted
Status updated on  17.04.2020
FormerGrant of patent is intended
Status updated on  12.12.2019
FormerExamination is in progress
Status updated on  03.11.2017
Most recent event   Tooltip19.12.2025Lapse of the patent in a contracting state
New state(s): TR		published on 21.01.2026  [2026/04]
Applicant(s)For all designated states
NX Pharmagen
4350 Brownsboro Road
Suite 110
Louisville, KY 40207 / US
[2016/13]
Inventor(s)01 / EZRIN, Alan, M.
1827 South Bayshore Lane
Miami, FL 33133 / US
02 / GRIFFITHS, Steven, G.
239 Weldon Street
Moncton, New Brunswick E1C 5W8 / CA
 [2016/13]
Representative(s)Zacco Sweden AB
P.O. Box 5581
Löjtnantsgatan 21
114 85 Stockholm / SE
[N/P]
Former [2016/13]Zacco Sweden AB
P.O. Box 5581
114 85 Stockholm / SE
Application number, filing date14800752.919.05.2014
[2016/13]
WO2014US38615
Priority number, dateUS201361825951P21.05.2013         Original published format: US 201361825951 P
[2016/13]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2014189842
Date:27.11.2014
Language:EN
[2014/48]
Type: A2 Application without search report 
No.:EP2999967
Date:30.03.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 27.11.2014 takes the place of the publication of the European patent application.
[2016/13]
Type: B1 Patent specification 
No.:EP2999967
Date:20.05.2020
Language:EN
[2020/21]
Search report(s)International search report - published on:US29.10.2015
(Supplementary) European search report - dispatched on:EP07.12.2016
ClassificationIPC:G01N33/574
[2016/13]
CPC:
G01N33/57585 (EP,US); G01N33/57557 (EP,US); G01N2333/4703 (US);
G01N2333/78 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/13]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERWENDUNG VON TENASCIN-C ALS EXTRAZELLULÄRER MARKER FÜR AUS TUMOREN GEWONNENEN MIKROPARTIKELN[2016/13]
English:USE OF TENASCIN-C AS AN EXTRACELLULAR MARKER OF TUMOR-DERIVED MICROPARTICLES[2016/13]
French:UTILISATION DE LA TÉNASCINE-C COMME MARQUEUR EXTRACELLULAIRE DE MICROPARTICULES DÉRIVÉES DE TUMEURS[2016/13]
Entry into regional phase03.12.2015National basic fee paid 
03.12.2015Search fee paid 
03.12.2015Designation fee(s) paid 
03.12.2015Examination fee paid 
Examination procedure03.12.2015Examination requested  [2016/13]
22.06.2017Amendment by applicant (claims and/or description)
03.11.2017Despatch of a communication from the examining division (Time limit: M06)
11.06.2018Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
17.08.2018Reply to a communication from the examining division
23.11.2018Despatch of a communication from the examining division (Time limit: M04)
03.04.2019Reply to a communication from the examining division
13.12.2019Communication of intention to grant the patent
09.04.2020Fee for grant paid
09.04.2020Fee for publishing/printing paid
09.04.2020Receipt of the translation of the claim(s)
Opposition(s)23.02.2021No opposition filed within time limit [2021/17]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
17.08.2018Request for further processing filed
17.08.2018Full payment received (date of receipt of payment)
Request granted
29.08.2018Decision despatched
Fees paidRenewal fee
25.05.2016Renewal fee patent year 03
10.05.2017Renewal fee patent year 04
11.05.2018Renewal fee patent year 05
15.05.2019Renewal fee patent year 06
31.03.2020Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU19.05.2014
AL20.05.2020
AT20.05.2020
CY20.05.2020
CZ20.05.2020
DK20.05.2020
EE20.05.2020
ES20.05.2020
FI20.05.2020
HR20.05.2020
IT20.05.2020
LT20.05.2020
LV20.05.2020
MC20.05.2020
MK20.05.2020
MT20.05.2020
NL20.05.2020
PL20.05.2020
RO20.05.2020
RS20.05.2020
SE20.05.2020
SI20.05.2020
SK20.05.2020
SM20.05.2020
TR20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
[2026/04]
Former [2024/41]HU19.05.2014
AL20.05.2020
AT20.05.2020
CY20.05.2020
CZ20.05.2020
DK20.05.2020
EE20.05.2020
ES20.05.2020
FI20.05.2020
HR20.05.2020
IT20.05.2020
LT20.05.2020
LV20.05.2020
MC20.05.2020
MK20.05.2020
MT20.05.2020
NL20.05.2020
PL20.05.2020
RO20.05.2020
RS20.05.2020
SE20.05.2020
SI20.05.2020
SK20.05.2020
SM20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2024/22]HU19.05.2014
AL20.05.2020
AT20.05.2020
CY20.05.2020
CZ20.05.2020
DK20.05.2020
EE20.05.2020
ES20.05.2020
FI20.05.2020
HR20.05.2020
IT20.05.2020
LT20.05.2020
LV20.05.2020
MC20.05.2020
MK20.05.2020
NL20.05.2020
PL20.05.2020
RO20.05.2020
RS20.05.2020
SE20.05.2020
SI20.05.2020
SK20.05.2020
SM20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2023/30]HU19.05.2014
AL20.05.2020
AT20.05.2020
CY20.05.2020
CZ20.05.2020
DK20.05.2020
EE20.05.2020
ES20.05.2020
FI20.05.2020
HR20.05.2020
IT20.05.2020
LT20.05.2020
LV20.05.2020
MC20.05.2020
NL20.05.2020
PL20.05.2020
RO20.05.2020
RS20.05.2020
SE20.05.2020
SI20.05.2020
SK20.05.2020
SM20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2023/29]HU19.05.2014
AL20.05.2020
AT20.05.2020
CZ20.05.2020
DK20.05.2020
EE20.05.2020
ES20.05.2020
FI20.05.2020
HR20.05.2020
IT20.05.2020
LT20.05.2020
LV20.05.2020
MC20.05.2020
NL20.05.2020
PL20.05.2020
RO20.05.2020
RS20.05.2020
SE20.05.2020
SI20.05.2020
SK20.05.2020
SM20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2022/07]AL20.05.2020
AT20.05.2020
CZ20.05.2020
DK20.05.2020
EE20.05.2020
ES20.05.2020
FI20.05.2020
HR20.05.2020
IT20.05.2020
LT20.05.2020
LV20.05.2020
MC20.05.2020
NL20.05.2020
PL20.05.2020
RO20.05.2020
RS20.05.2020
SE20.05.2020
SI20.05.2020
SK20.05.2020
SM20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2021/24]AL20.05.2020
AT20.05.2020
CZ20.05.2020
DK20.05.2020
EE20.05.2020
ES20.05.2020
FI20.05.2020
HR20.05.2020
IT20.05.2020
LT20.05.2020
LV20.05.2020
NL20.05.2020
PL20.05.2020
RO20.05.2020
RS20.05.2020
SE20.05.2020
SI20.05.2020
SK20.05.2020
SM20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2021/10]AL20.05.2020
AT20.05.2020
CZ20.05.2020
DK20.05.2020
EE20.05.2020
ES20.05.2020
FI20.05.2020
HR20.05.2020
IT20.05.2020
LT20.05.2020
LV20.05.2020
NL20.05.2020
PL20.05.2020
RO20.05.2020
RS20.05.2020
SE20.05.2020
SK20.05.2020
SM20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2021/09]AL20.05.2020
AT20.05.2020
CZ20.05.2020
DK20.05.2020
EE20.05.2020
ES20.05.2020
FI20.05.2020
HR20.05.2020
IT20.05.2020
LT20.05.2020
LV20.05.2020
NL20.05.2020
RO20.05.2020
RS20.05.2020
SE20.05.2020
SM20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2021/08]AL20.05.2020
DK20.05.2020
ES20.05.2020
FI20.05.2020
HR20.05.2020
LT20.05.2020
LV20.05.2020
NL20.05.2020
RO20.05.2020
RS20.05.2020
SE20.05.2020
SM20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2021/04]AL20.05.2020
FI20.05.2020
HR20.05.2020
LT20.05.2020
LV20.05.2020
NL20.05.2020
RS20.05.2020
SE20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2021/01]FI20.05.2020
HR20.05.2020
LT20.05.2020
LV20.05.2020
RS20.05.2020
SE20.05.2020
BG20.08.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2020/51]FI20.05.2020
HR20.05.2020
LT20.05.2020
LV20.05.2020
RS20.05.2020
SE20.05.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2020/50]FI20.05.2020
HR20.05.2020
LT20.05.2020
LV20.05.2020
SE20.05.2020
NO20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2020/48]FI20.05.2020
LT20.05.2020
SE20.05.2020
NO20.08.2020
IS20.09.2020
PT21.09.2020
Former [2020/47]LT20.05.2020
NO20.08.2020
IS20.09.2020
Former [2020/46]IS20.09.2020
Documents cited:Search[XI] US2010196426  (SKOG JOHAN KARL OLOV et al.) [X] 2 * paragraph [0047] - paragraph [0052]; figure 3d; claims 1-50 * * paragraph [0182] *[I] 2-18
 [A] WO2012170711  (CARIS LIFE SCIENCES LUXEMBOURG HOLDINGS S A R L et al.) [A] 1-18 * paragraph [0028] * * paragraph [00189] *
 [XA]   HONG JI ET AL: "Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components", PROTEOMICS, vol. 13, no. 10-11, 1 May 2013 (2013-05-01), DE, pages 1672 - 1686, XP055321815, ISSN: 1615-9853, DOI: 10.1002/pmic.201200562 [X] 1 * abstract * * page 1673, column l, paragraph 3 * * page 1679, column l * [A] 2-18

DOI:   http://dx.doi.org/10.1002/pmic.201200562
 [A]   IAN CHUTE ET AL: "Novel Peptide with affinity for canonical heat shock proteins (HSPs) as a tool for capture and enrichment of extracellular microvesicles", 1 April 2013 (2013-04-01), XP055322663, Retrieved from the Internet [retrieved on 20161124] [A] 1-18 * the whole document *
 [A]   HOSSEINI-BEHESHTI ELHAM ET AL: "Exosomes as biomarker enriched microvesicles: characterization of exosomal proteins derived from a panel of prostate cell lines with distinct AR phenotypes", MOLECULAR & CELLULAR PROTEOMICS, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 11, no. 10, 1 October 2012 (2012-10-01), pages 863 - 885, XP009171110, ISSN: 1535-9476, [retrieved on 20120621], DOI: 10.1074/MCP.M111.014845 [A] 1-18 * table 2 *

DOI:   http://dx.doi.org/10.1074/mcp.M111.014845
 [A]   CLAUDIA CHAVEZ-MUOZ ET AL: "Profile of exosomes related proteins released by differentiated and undifferentiated human keratinocytes", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 221, no. 1, 1 October 2009 (2009-10-01), pages 221 - 231, XP055195376, ISSN: 0021-9541, DOI: 10.1002/jcp.21847 [A] 1-18 * table 1 *

DOI:   http://dx.doi.org/10.1002/jcp.21847
 [A]   GAMBIM MARCELA HELENA ET AL: "Platelet-derived exosomes induce endothelial cell apoptosis through peroxynitrite generation: experimental evidence for a novel mechanism of septic vascular dysfunction", CRITICAL CARE, BIOMED CENTRAL LTD., LONDON, GB, vol. 11, no. 5, 25 September 2007 (2007-09-25), pages R107, XP021041350, ISSN: 1364-8535 [A] 1-18 * the whole document *
International search[X] WO2012170711  (CARIS LIFE SCIENCES LUXEMBOURG HOLDINGS S A R L et al.) [X] 1-3, 5-8 * entire document *
 [P,X] US2013330753  (EZRIN ALAN M et al.) [P,X] 1-3, 5-8 * entire document *
 [P,X] WO2013184830  (PIOMA INC et al.) [P,X] 1-3, 5-8 * entire document *
 [A] US2010196426  (SKOG JOHAN KARL OLOV et al.) [A] 1-3, 5-8 * entire document *
Examination  VALADI H ET AL: "Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells", NATURE CELL BIOLOGY, MACMILLAN MAGAZINES LTD, GB, vol. 9, no. 6, 6 June 2007 (2007-06-06), pages 654 - 659, XP003016816, ISSN: 1465-7392, DOI: 10.1038/NCB1596 [I] 2-18

DOI:   http://dx.doi.org/10.1038/ncb1596
   MONIKA BAJ-KRZYWORZEKA ET AL: "Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 55, no. 7, 9 November 2005 (2005-11-09), pages 808 - 818, XP055176484, ISSN: 0340-7004, DOI: 10.1007/s00262-005-0075-9 [X] 1 * abstract * * page 1673, column l, paragraph 3 * * page 1679, column l * [A] 2-18

DOI:   http://dx.doi.org/10.1007/s00262-005-0075-9
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.